Surfactant for the Treatment of ARDS in a Patient With COVID-19

被引：24

作者：

Heching, Moshe ^{[1
]}

Lev, Shaul ^{[2
,3
]}

Shitenberg, Dorit ^{[1
]}

Dicker, Dror ^{[2
,3
]}

Kramer, Mordechai R. ^{[1
]}

机构：

[1] Rabin Med Ctr, Beilinson Hosp, Dept Intens Care, Petah Tiqwa, Israel

[2] Rabin Med Ctr, Dept Pulm, Dept Intens Care, Petah Tiqwa, Israel

[3] Rabin Med Ctr, Sharon Hosp, Dept Intens Care, Petah Tiqwa, Israel

来源：

CHEST | 2021年 / 160卷 / 01期

关键词：

ARDS; COVID-19; surfactant; RESPIRATORY-DISTRESS-SYNDROME;

D O I：

10.1016/j.chest.2021.01.028

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Patients with COVID-19 report severe respiratory symptoms consistent with ARDS. The clinical presentation of ARDS in COVID-19 is often atypical, as patients with COVID-19 exhibit a disproportionate hypoxemia compared with relatively preserved lung mechanics. This pattern is more similar to neonatal respiratory distress syndrome secondary to surfactant deficiency, which has been shown to benefit from exogenous surfactant. We present our experience with exogenous surfactant treatment in a patient with COVID-19 experiencing COVID-19-related ARDS. The patient responded with improved oxygenation, and we believe surfactant was the catalyst for the successful extubation and clinical improvement of the patient.

引用

页码：E9 / E12

页数：4

共 20 条

[1] The Use of Surfactant in Lung Transplantation [J].

Amital, Anat ;

Shitrit, David ;

Raviv, Yael ;

Saute, Milton ;

Medalion, Benjamin ;

Bakal, Ilana ;

Kramer, Mordechai R. .

TRANSPLANTATION, 2008, 86 (11) :1554-1559

[2]

Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI [10.1056/NEJMoa2007764, 10.1056/NEJMc2022236]

[3] Surfactant replacement might help recovery of low-compliance lung in severe COVID-19 pneumonia [J].

Busani, Stefano ;

Dall'Ara, Lorenzo ;

Tonelli, Roberto ;

Clini, Enrico ;

Munari, Elena ;

Venturelli, Sophie ;

Meschiari, Marianna ;

Guaraldi, Giovanni ;

Cossarizza, Andrea ;

Ranieri, V. Marco ;

Girardis, Massimo .

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2020, 14

[4] The pathophysiology of 'happy' hypoxemia in COVID-19 [J].

Dhont, Sebastiaan ;

Derom, Eric ;

Van Braeckel, Eva ;

Depuydt, Pieter ;

Lambrecht, Bart N. .

RESPIRATORY RESEARCH, 2020, 21 (01)

[5] COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome [J].

Gattinoni, Luciano ;

Coppola, Silvia ;

Cressoni, Massimo ;

Busana, Mattia ;

Rossi, Sandra ;

Chiumello, Davide .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201 (10) :1299-1300

[6] SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [J].

Hoffmann, Markus ;

Kleine-Weber, Hannah ;

Schroeder, Simon ;

Krueger, Nadine ;

Herrler, Tanja ;

Erichsen, Sandra ;

Schiergens, Tobias S. ;

Herrler, Georg ;

Wu, Nai-Huei ;

Nitsche, Andreas ;

Mueller, Marcel A. ;

Drosten, Christian ;

Poehlmann, Stefan .

CELL, 2020, 181 (02) :271-+

[7]

Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]

[8] Lung transcriptome of a COVID-19 patient and systems biology predictions suggest impaired surfactant production which may be druggable by surfactant therapy [J].

Islam, Abul Bashar Mir Md Khademul ;

Khan, Md Abdullah-Al-Kamran .

SCIENTIFIC REPORTS, 2020, 10 (01)

[9]

Jiang T, 2017, BIOMEDICAL RES, V28, P9801

[10] Lung Mechanics in COVID-19 Resemble Respiratory Distress Syndrome, Not Acute Respiratory Distress Syndrome: Could Surfactant Be a Treatment? [J].

Koumbourlis, Anastassios C. ;

Motoyama, Etsuro K. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 202 (04) :624-626

← 1 2 →